Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$47.76 USD

47.76
2,535,254

+0.81 (1.73%)

Updated Aug 1, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PRFZ

Zacks Equity Research

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.

Zacks Equity Research

The Zacks Analyst Blog Highlights DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences

by Zacks Equity Research

DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences are part of the Zacks top Analyst Blog.

Nalak Das headshot

Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left

by Nalak Das

We have narrowed our search to five Nasdaq Composite listed non-technology stocks. These are: CELH, DKNG, CPRT, EXAS, MAR.

Zacks Equity Research

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

Zacks Equity Research

Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.

Zacks Equity Research

Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strategic executions on the United States and the international front is likely to drive Walgreens' (WBA) Q3 revenues.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Exact Sciences (EXAS) is a Great Choice

by Zacks Equity Research

Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Zacks Equity Research

If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PRFZ

Zacks Equity Research

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Zacks Equity Research

If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised

by Zacks Equity Research

The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.

Zacks Equity Research

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PRFZ

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Zacks.com featured highlights ColgatePalmolive, BigCommerce and Exact Sciences

by Zacks Equity Research

ColgatePalmolive, BigCommerce and Exact Sciences have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Top Earnings Acceleration Stocks Worth Buying

by Tirthankar Chakraborty

Notable companies to have witnessed solid earnings acceleration as of now are ColgatePalmolive (CL), BigCommerce (BIGC) & Exact Sciences (EXAS).